Screener
Pulse Biosciences, Inc. PLSE Business Segments — Clinical And Regulatory
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pulse Biosciences, Inc. in its filing.
Tagged under the XBRL concept plse:ClinicalAndRegulatory.
The source filing: Pulse Biosciences, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:23 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-026288
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Adjusted cost of product revenue1 | 245 | — | 571 | — |
| Cross platform research and engineering2 | 6,078 | 4,585 | 11,258 | 8,535 |
| R&D manufacturing and engineering3 | 3,201 | 2,941 | 5,550 | 4,736 |
| Clinical and regulatory4 | 5,127 | 2,183 | 8,387 | 3,943 |
| General and administrative5 | 4,548 | 2,742 | 8,490 | 5,461 |
| Sales and marketing6 | 1,279 | 2,362 | 3,607 | 4,218 |
| Other segment items7 | 5,228 | 5,462 | 7,394 | 11,426 |
| Total other income, net | (615) | (1,107) | (1,184) | (2,356) |
Document
FAQ
- What is Pulse Biosciences, Inc.'s business segments — clinical and regulatory?
- Pulse Biosciences, Inc. (PLSE) reported business segments — clinical and regulatory of $5.13M in Q2 2026.
- What does business segments — clinical and regulatory mean?
- This encompasses the costs related to conducting clinical trials and navigating regulatory approval processes for new medical technologies. These expenditures are critical for ensuring compliance and market access for the company's bioelectric innovations.
Ask your AI about Pulse Biosciences, Inc.'s business segments — clinical and regulatory.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude